文献速递生殖医学妇科

早发性女性癌症幸存者IVF/ICSI后活产概率:芬兰人群登记研究

Probability of live birth after IVF/ICSI treatments in female early onset cancer survivors: a Finnish population-based registry study.
PubMed 文献 · Hum Reprod · 2021-01-01

该回顾性登记研究纳入8944例0-40岁确诊的早发性女性癌症幸存者和9848例姐妹,比较1993-2012年间新鲜IVF/ICSI周期的活产率。幸存者总体活产率低于姐妹(IRR 0.68,95%CI 0.64-0.71),但接受IVF/ICSI者四个周期后活产概率与姐妹无显著差异。

要点

  • 癌症幸存者总体活产率低于姐妹(IRR 0.68,95%CI 0.64-0.71),与是否接受IVF/ICSI无关。
  • 首个新鲜IVF/ICSI周期活产率幸存者17.2% vs 姐妹15.7%(RR 1.13,95%CI 0.72-1.87)。
  • 四个新鲜IVF/ICSI周期后平均活产率在幸存者与姐妹间无统计学差异。

核心结论

  • 接受IVF/ICSI治疗的早发性女性癌症幸存者,其活产概率与接受IVF/ICSI治疗的姐妹相似。
  • 但幸存者总体活产率低于姐妹,提示接受IVF/ICSI的幸存者属于卵巢储备至少中等的选择人群。

研究设计与样本

  • 回顾性登记研究,合并芬兰癌症、出生和处方药物登记数据。
  • 纳入8944例1953-2012年确诊、年龄0-40岁的女性癌症幸存者和9848例姐妹。
  • 分析1993年1月至2012年12月间年龄20-41岁者的新鲜IVF/ICSI周期及22-48周内活产。
  • 采用二项回归模型计算活产风险比(RR),泊松回归模型估算IVF/ICSI治疗及总体活产的发病率比(IRR)。

主要发现

  • 幸存者总体活产率低于姐妹(IRR 0.68,95%CI 0.64-0.71),不考虑IVF/ICSI治疗。
  • 179例(2.0%)幸存者和230例(2.3%)姐妹被处方IVF/ICSI生育药物(IRR 0.72,95%CI 0.62-0.84)。
  • 首个新鲜IVF/ICSI周期活产率:幸存者17.2%,姐妹15.7%(RR 1.13,95%CI 0.72-1.87)。
  • 四个新鲜IVF/ICSI周期后平均活产率在幸存者与姐妹间无统计学差异。

临床怎么用

  • 对于接受IVF/ICSI的早发性癌症幸存者,可告知其活产概率与接受IVF/ICSI的姐妹相似。
  • 应认识到幸存者总体活产率较低,接受IVF/ICSI者可能代表卵巢储备至少中等的人群。

局限性

  • 仅纳入自体卵母细胞的新鲜IVF/ICSI治疗,未评估冻融胚胎移植或卵母细胞捐赠后的活产概率。
  • 缺乏流产、宫外孕或终止妊娠的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the probability of a live birth after fresh IVF/ICSI cycles with autologous oocytes differ in early onset female cancer survivors compared to their siblings? SUMMARY ANSWER: The probability of a live birth was similar in female cancer survivors and siblings after four fresh IVF/ICSI cycles. WHAT IS KNOWN ALREADY: Fertility preservation strategies are rapidly being developed to help female cancer patients who wish to have children later. However, there are only a few studies available on fertility treatments and following live births in female cancer survivors before fertility preservation strategies became available. In one of them, the probability of a live birth was reduced after assisted reproductive technology with autologous oocytes in cancer survivors compared to siblings. STUDY DESIGN, SIZE, DURATION: In this retrospective, register-based study, data from Finnish registers on cancer, birth and prescribed medications were merged to identify 8944 female cancer survivors (diagnosed with cancer between 1953 and 2012 at the age of 0-40 years) and 9848 female siblings of survivors eligible for IVF/ICSI treatments between January 1993 and December 2012. PARTICIPANTS/MATERIALS, SETTING, METHODS: Fresh IVF/ICSI cycles and following live birth rates (LBRs) within 22-48 weeks in cancer survivors and siblings at the age of 20-41 years were identified. A binomial regression model with log-link function was used to calculate risk ratio (RR) for live births after fresh IVF/ICSI cycles in survivors compared to siblings, adjusting for attained age and calendar time. A Poisson regression model was used to estimate incidence rate ratios (IRRs) for an IVF/ICSI treatment, as well as overall live births, including both pregnancies after fertility treatments and spontaneous pregnancies, in survivors compared to siblings. MAIN RESULTS AND THE ROLE OF CHANCE: We observed an overall decreased LBR, irrespective of IVF/ICSI treatments, in cancer survivors compared to siblings (IRR 0.68, 95% CI 0.64-0.71). All in all, 179 (2.0%) survivors and 230 (2.3%) siblings were prescribed fertility drugs for IVF/ICSI treatments (IRR 0.72, 95% CI 0.62-0.84). For the first fresh IVF/ICSI cycle, the LBR was 17.2% among survivors and 15.7% among siblings (RR 1.13, 95% CI 0.72-1.87). The mean LBR after four fresh IVF/ICSI cycles was not statistically different in survivors compared to siblings. LIMITATIONS, REASONS FOR CAUTION: In this study, only IVF/ICSI treatments with autologous oocytes were included. The probability of a live birth after a frozen embryo transfer or oocyte donation could not be evaluated in this study. Information on miscarriages, extrauterine pregnancies or termination of pregnancies was not available. WIDER IMPLICATIONS OF THE FINDINGS: For those early onset cancer survivors, who received IVF/ICSI treatments, the probability of live birth was not different from siblings who received IVF/ICSI treatments. However, an overall decreased LBR, irrespective of IVF/ICSI treatments, was observed in cancer survivors compared to siblings, indicating that cancer survivors receiving IVF/ICSI treatments in our study consisted of a selected group with at least a moderate ovarian reserve. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by a grant from the Cancer Foundation (Finland) (grant number 130079) and by a grant from LähiTapiola. The authors have no potential conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Melin J, Tiitinen A, Hirvonen E, et al. Probability of live birth after IVF/ICSI treatments in female early onset cancer survivors: a Finnish population-based registry study. Hum Reprod. 2021. PMID: 34491339. doi:10.1093/humrep/deab202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。